tnmynatt Posted June 7, 2005 Share Posted June 7, 2005 Genentech/Roche's Avastin Will Account for More Than 50% of the Non-Small-Cell Lung Cancer Drug Market in 2014 http://www.prnewswire.com/cgi-bin/stori ... 144&EDATE= Generics Erosion Threatens Three Major Drugs in the Lung Cancer Market, According to a New Study from Decision Resources Waltham, Mass., June 7 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Genentech/Roche's Avastin will account for more than 50% of the non-small-cell lung cancer drug market in 2014. "Novel, targeted biological therapies, such as the anti-angiogenic monoclonal antibody bevacizumab (Genentech/Roche's Avastin), will further expand treatment options for advanced disease," said Mohammed Muhsin, analyst at Decision Resources, Inc. "Avastin will be launched in 2006 and will be the main driver of the non-small-cell lung cancer market from 2009 to 2014." The new Pharmacor study entitled Non-Small-Cell Lung Cancer also finds that generics erosion will threaten three major drugs in the non-small-cell lung cancer drug market. The recent patent expiry of carboplatin in the United States and patient expiries of Sanofi-Aventis's docetaxel and Eli Lilly's gemcitabine in the United States and other markets will constrain the market value of these agents. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.